Microbiomic and Posttranslational Modifications as Preludes to Autoimmune Diseases

Trends in Molecular Medicine

Volumn 22, Issue 9, 2016, Pages 746-757

  Opdenakker, Ghislain ^a,b,c   Proost, Paul ^a,b   Van Damme, Jo ^a,b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

antigen; arthritis; citrullination; diabetes; glycation; glycosidase; glycosyl transferase; glycosylation; multiple sclerosis; peptidylarginine deiminase; proteases; remnant epitopes; systemic lupus erythematosus

Indexed keywords

AUTOANTIGEN; PROTEINASE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; CITRULLINATION; ENVIRONMENTAL FACTOR; GLYCOSYLATION; HUMAN; INNATE IMMUNITY; MICROFLORA; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROCESSING; REVIEW; T LYMPHOCYTE ACTIVATION; ANIMAL; IMMUNITY; IMMUNOLOGY; METABOLISM; MICROBIOLOGY;

ANIMALS; AUTOANTIGENS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNITY; IMMUNITY, INNATE; MICROBIOTA; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOLYSIS;

EID: 84991010655     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.07.002     Document Type: Review

References (87)

1. 1 Melchers, F., et al. Repertoire selection by pre-B-cell receptors and B-cell receptors, and genetic control of B-cell development from immature to mature B cells. Immunol. Rev. 175 (2000), 33–46.
2. 2 Benoist, C., Mathis, D., Generation of the alpha beta T-cell repertoire. Curr. Opin. Immunol. 4 (1992), 156–161.
3. 3 Rossjohn, J., et al. T cell antigen receptor recognition of antigen-presenting molecules. Annu. Rev. Immunol. 33 (2015), 169–200.
4. 4 Nitzsche, R., et al. Streptococcus pyogenes triggers activation of the human contact system by streptokinase. Infect. Immun. 83 (2015), 3035–3042.
5. 5 Haiko, J., et al. Breaking barriers – attack on innate immune defences by omptin surface proteases of enterobacterial pathogens. Innate Immun. 15 (2009), 67–80.
6. 6 Opdenakker, G., Van Damme, J., Cytokine-regulated proteases in autoimmune diseases. Immunol. Today 15 (1994), 103–107.
7. 7 Paemen, L., et al. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur. J. Neurol. 1 (1994), 55–63.
8. 8 Proost, P., et al. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192 (1993), 1175–1181.
9. 9 Dubois, B., et al. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 104 (1999), 1507–1515.
10. 10 Agrawal, S., et al. Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J. Exp. Med. 203 (2006), 1007–1019.
11. 11 Van den Steen, P.E., et al. Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post-translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis. FASEB J. 16 (2002), 379–389.
12. 12 Myers, L.K., et al. Collagen-induced arthritis, an animal model of autoimmunity. Life Sci. 61 (1997), 1861–1878.
13. 13 Itoh, T., et al. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J. Immunol. 169 (2002), 2643–2647.
14. 14 Opdenakker, G., Van Damme, J., Probing cytokines, chemokines and matrix metalloproteinases towards better immunotherapies of multiple sclerosis. Cytokine Growth Factor Rev. 22 (2011), 359–365.
15. 15 Descamps, F.J., et al. Gelatinase B is diabetogenic in acute and chronic pancreatitis by cleaving insulin. FASEB J. 17 (2003), 887–889.
16. 16 Hu, J., et al. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov. 6 (2007), 480–498.
17. 17 Paemen, L., et al. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. Biochem. Pharmacol. 52 (1996), 105–111.
18. 18 Marshall, D.C., et al. Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer. PLoS ONE, 10, 2015, e0127063.
19. 19 Laine, R.A., Rush, J.S., Chemistry of human erythrocyte polylactosamine glycopeptides (erythroglycans) as related to ABH blood group antigenic determinants. Adv. Exp. Med. Biol. 228 (1988), 331–347.
20. 20 Rudd, P.M., Dwek, R.A., Rapid, sensitive sequencing of oligosaccharides from glycoproteins. Curr. Opin. Biotechnol. 8 (1997), 488–497.
21. 21 Parekh, R.B., et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316 (1985), 452–457.
22. 22 Anthony, R.M., et al. Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320 (2008), 373–376.
23. 23 Malhotra, R., et al. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat. Med. 1 (1995), 237–243.
24. 24 Fiebiger, B.M., et al. Protection in antibody- and T cell-mediated autoimmune diseases by antiinflammatory IgG Fcs requires type II FcRs. Proc. Natl. Acad. Sci. U.S.A. 112 (2015), E2385–E2394.
25. 25 Martin, R., et al. Molecular mimicry and antigen-specific T cell responses in multiple sclerosis and chronic CNS Lyme disease. J. Autoimmun. 16 (2001), 187–192.
26. 26 Michaëlsson, E., et al. Antigen processing and presentation of a naturally glycosylated protein elicits major histocompatibility complex class II-restricted, carbohydrate-specific T cells. Eur. J. Immunol. 26 (1996), 1906–1910.
27. 27 Bäcklund, J., et al. Predominant selection of T cells specific for the glycosylated collagen type II epitope (263-270) in humanized transgenic mice and in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 99 (2002), 9960–9965.
28. 28 Haurum, J.S., Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180 (1994), 739–744.
29. 29 Van den Steen, P.E., et al. Concepts and principles of O-linked glycosylation. Crit. Rev. Biochem. Mol. Biol. 33 (1998), 151–208.
30. 30 Petersson, S.B., Hart, G.W., New insights: a role for O-GlcNAcylation in diabetes complications. Crit. Rev. Biochem. Mol. Biol. 51 (2016), 150–161.
31. 31 Moelants, E., et al. Peptidylarginine deiminases: physiological function, interaction with chemokines and role in pathology. Drug Discov. Today Technol. 9 (2012), e261–e290.
32. 32 Ishigami, A., Maruyama, N., Importance of research on peptidylarginine deiminase and citrullinated proteins in age-related disease. Geriatr. Gerontol. Int. 10 (2010), S53–S58.
33. 33 Proost, P., et al. Citrullination of CXCL8 by peptidyl arginine deiminase alters receptor usage, prevents proteolysis and dampens tissue inflammation. J. Exp. Med. 205 (2008), 2085–2097.
34. 34 Wang, Y., et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184 (2009), 205–213.
35. 35 Loos, T., et al. Citrullination of CXCL10 and CXCL11 by peptidylarginine deiminase: a naturally occurring posttranslational modification of chemokine and new dimension of immunoregulation. Blood 112 (2008), 2648–2656.
36. 36 Vossenaar, E.R., et al. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 25 (2003), 1106–1118.
37. 37 Moscarello, M.A., et al. The role of citrullinated proteins suggests a novel mechanism in the pathogenesis of multiple sclerosis. Neurochem. Res. 32 (2007), 251–256.
38. 38 Harauz, G., Musse, A.A., A tale of two citrullines – structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem. Res. 32 (2007), 137–158.
39. 39 Jin, Z., et al. Identification and characterization of citrulline-modified brain proteins by combining HCD and CID fragmentation. Proteomics 13 (2013), 2682–2691.
40. 40 Cao, L., et al. Rapid release and unusual stability of immunodominant peptide 45-89 from citrullinated myelin basic protein. Biochemistry 38 (1999), 6157–6163.
41. 41 Yamada, R., et al. Peptidylarginine deiminase type 4: identification of a rheumatoid arthritis-susceptible gene. Trends Mol. Med. 9 (2003), 503–508.
42. 42 Schellekens, G.A., et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J. Clin. Invest. 101 (1998), 273–281.
43. 43 van Venrooij, W.J., Pruijn, G.J., Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res. 2 (2000), 249–251.
44. 44 Jansen, A.L.M.A., et al. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J. Rheumatol. 29 (2002), 2074–2076.
45. 45 Wegner, N., et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 233 (2010), 34–54.
46. 46 Lu, M.C., et al. Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production. Arthritis Rheum. 62 (2010), 1213–1223.
47. 47 Panayi, G.S., Corrigall, V.M., Immunoglobulin heavy-chain-binding protein (BiP): a stress protein that has the potential to be a novel therapy for rheumatoid arthritis. Biochem. Soc. Trans. 42 (2014), 1752–1755.
48. 48 Rondas, D., et al. Citrullinated glucose-regulated protein 78 is an autoantigen in type 1 diabetes. Diabetes 64 (2015), 573–586.
49. 49 Hooper, L.V., et al. Interactions between the microbiota and the immune system. Science 336 (2012), 1268–1273.
50. 50 Hergott, C.B., et al. Peptidoglycan from the gut microbiota governs the lifespan of circulating phagocytes at homeostasis. Blood 127 (2016), 2460–2471.
51. 51 Vatanen, T., et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 165 (2016), 842–853.
52. 52 Yang, Y., et al. Focused specificity of intestinal TH17 cells towards commensal bacterial antigens. Nature 510 (2014), 152–156.
53. 53 Wen, L., et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455 (2008), 1109–1113.
54. 54 Wu, H.J., et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32 (2010), 815–827.
55. 55 Lee, Y.K., et al. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U.S.A. 108:Suppl. 1 (2011), 4615–4622.
56. 56 Steck, N., et al. Bacterial proteases in IBD and IBS. Gut 61 (2012), 1610–1618.
57. 57 Potempa, J., et al. Role of bacterial proteinases in matrix destruction and modulation of host responses. Periodontology 24 (2000), 153–192.
58. 58 Hritonenko, V., Stathopoulos, C., Omptin proteins: an expanding family of outer membrane proteases in Gram-negative Enterobacteriaceae. Mol. Membr. Biol. 24 (2007), 395–406.
59. 59 Lundberg, K., et al. Periodontitis in RA – the citrullinated enolase connection. Nat. Rev. Rheumatol. 6 (2010), 727–730.
60. 60 Kinloch, A.J., et al. Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian α-enolase and arthritis in DR4-IE-transgenic mice. Arthritis Rheum. 63 (2011), 3818–3823.
61. 61 Goulas, T., et al. Structure and mechanism of a bacterial host-protein citrullinating virulence factor, Porphyromonas gingivalis peptidylarginine deiminase. Sci. Rep., 5, 2015, 11969.
62. 62 Koziel, J., et al. The link between periodontal disease and rheumatoid arthritis: an updated review. Curr. Rheumatol. Rep., 16, 2014, 408.
63. 63 Moelants, E.A., et al. Citrullination and proteolytic processing of chemokines by Porphyromonas gingivalis. Infect. Immun. 82 (2014), 2511–2519.
64. 64 Bielecka, E., et al. Peptidyl arginine deiminase from Porphyromonas gingivalis abolishes anaphylatoxin C5a activity. J. Biol. Chem. 289 (2014), 32481–32487.
65. 65 Koziel, J., et al. Citrullination alters immunomodulatory function of LL-37 essential for prevention of endotoxin-induced sepsis. J. Immunol. 192 (2014), 5363–5372.
66. 66 Maresz, K.J., et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog., 9, 2013, e1003627.
67. 67 Smith, K., et al. One step closer to understanding the role of bacteria in diabetic foot ulcers: characterising the microbiome of ulcers. BMC Microbiol., 16, 2016, 54.
68. 68 Moscarello, M.A., et al. Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis. Dis. Model. Mech. 6 (2013), 467–478.
69. 69 Cauwe, B., Opdenakker, G., Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit. Rev. Biochem. Mol. Biol. 45 (2010), 351–423.
70. 70 Cauwe, B., et al. Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease. J. Autoimmun. 36 (2011), 239–252.
71. 71 Robey, E., Fowlkes, B.J., Selective events in T cell development. Annu. Rev. Immunol. 12 (1994), 675–705.
72. 72 Moudgil, K.D., Sercarz, E.E., The T cell repertoire against cryptic self determinants and its involvement in autoimmunity and cancer. Clin. Immunol. Immunopathol. 73 (1994), 283–289.
73. 73 Freigang, S., et al. Endogenous neosynthesis vs cross-presentation of viral antigens for cytotoxic T cell priming. Proc. Natl. Acad. Sci. U.S.A. 100 (2003), 13477–13482.
74. + memory T cells: functional modules for tailored immunity. Eur. J. Immunol. 39 (2009), 2076–2082.
75. 75 Mosmann, T.R., et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136 (1986), 2348–2357.
76. 76 Metzger, T.C., Anderson, M.S., Control of central and peripheral tolerance by Aire. Immunol. Rev. 241 (2011), 89–103.
77. 77 Fulthorpe, A.J., et al. A stable sheep cell preparation for detecting thyroglobulin auto-antibodies and its clinical applications. J. Clin. Pathol. 14 (1961), 654–660.
78. 78 Deitiker, P., Atassi, M.Z., MHC genes linked to autoimmune diseases. Crit. Rev. Immunol. 35 (2015), 203–251.
79. 79 Johar, A.S., et al. Candidate gene discovery in autoimmunity by using extreme phenotypes, next generation sequencing and whole exome capture. Autoimmun. Rev. 14 (2015), 204–209.
80. 80 Agmon-Levin, N., et al. Vitamin D in systemic and organ-specific autoimmune diseases. Clin. Rev. Allergy Immunol. 45 (2013), 256–266.
81. 81 Riccio, P., The molecular basis of nutritional intervention in multiple sclerosis: a narrative review. Complement. Ther. Med. 19 (2011), 228–237.
82. 82 Perricone, C., et al. Smoke and autoimmunity: the fire behind the disease. Autoimmun. Rev. 15 (2016), 354–374.
83. 83 Belkaid, Y., Hand, T.W., Role of the microbiota in immunity and inflammation. Cell 157 (2014), 121–141.
84. 84 Yurkovetskiy, L.A., et al. Microbiota and autoimmunity: exploring new avenues. Cell Host Microbe 17 (2015), 548–552.
85. 85 Van Praet, J.T., et al. Commensal microbiota influence systemic autoimmune responses. EMBO J. 34 (2015), 466–474.
86. 86 Ruff, W.E., Kriegel, M.A., Autoimmune host–microbiota interactions at barrier sites and beyond. Trends Mol. Med. 21 (2015), 233–244.
87. 87 Foxman, E.F., Iwasaki, A., Genome–virome interactions: examining the role of common viral infections in complex disease. Nat. Rev. Microbiol. 9 (2011), 254–264.